Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

West Nile Virus Infections-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

West Nile Virus Infections-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

West Nile Virus Infections-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

West Nile Virus Infections-Pipeline Review, H1 2017



Executive Summary

West Nile Virus Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections-Pipeline Review, H1 2017, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.

West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide West Nile Virus Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively.

West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

West Nile Virus Infections-Overview

West Nile Virus Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

West Nile Virus Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

West Nile Virus Infections-Companies Involved in Therapeutics Development

CEL-SCI Corp

Fab'entech SA

Hemispherx Biopharma Inc

Kineta Inc

Nanotherapeutics Inc

Plex Pharmaceuticals Inc

Theravectys SA

West Nile Virus Infections-Drug Profiles

AGS-v-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alferon LDO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BG-323-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HydroVax-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-n3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1148-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for West Nile Virus Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Viral Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Dengue Virus and West Nile Virus Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tatbeclin-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile virus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile virus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile virus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile Virus Infections-Dormant Projects

West Nile Virus Infections-Product Development Milestones

Featured News & Press Releases

Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate

Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials

May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro

Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena

Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection

Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for West Nile Virus Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for West Nile Virus Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

West Nile Virus Infections-Pipeline by CEL-SCI Corp, H1 2017

West Nile Virus Infections-Pipeline by Fab'entech SA, H1 2017

West Nile Virus Infections-Pipeline by Hemispherx Biopharma Inc, H1 2017

West Nile Virus Infections-Pipeline by Kineta Inc, H1 2017

West Nile Virus Infections-Pipeline by Nanotherapeutics Inc, H1 2017

West Nile Virus Infections-Pipeline by Plex Pharmaceuticals Inc, H1 2017

West Nile Virus Infections-Pipeline by Theravectys SA, H1 2017

West Nile Virus Infections-Dormant Projects, H1 2017

West Nile Virus Infections-Dormant Projects, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

CEL-SCI Corp, Fab'entech SA, Hemispherx Biopharma Inc, Kineta Inc, Nanotherapeutics Inc, Plex Pharmaceuticals Inc, Theravectys SA


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand